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Background and natural history:
 Over ninety percent of cervical cancer across the world is 
caused by a virus (2).  This notorious culprit that ranked second in 
cancer-related deaths among  females across the world is named human 
papillomavirus (HPV) (2). HPV is a sexually transmitted, lysogenic, 
double stranded circular DNA (dsDNA) virus with approximately eight 
thousand base pairs (1, 9, 15, 16). HPV does not possess an envelope 
and has icosahedral capsids (18). It, like other papillomaviruses in its 
taxonomic family, both assembles and replicates in the nucleus of the 
host cell (17).  
 The basal cells of the stratified squamous epithelium and the 
metaplastic cells at the squamocolumnar junction in the cervix serve as 
HPV’s targets (15). Dissimilar to other types of genitourinary infections, 
HPV does not induce immediate symptoms upon infection (15 – 16). 
This is due to the host immune response to HPV infection (15). Given 
the recent discovery of a vaccine against this pathogen, various groups 
outside of the scientific community have turned their focus onto this 
virus. However, I would like to focus on the molecular infiltration this 
virus inflicts upon cervical epithelial cells. 
 HPV has a genome with three regions, the early (E), late (L), and 
non-coding long control region (LCR) (1, 9). The late region encodes for 
the structural proteins of the virus, while the LCR region, as implicated in 
the name, is for open reading frame (ORF) expression control (1). 
 It must be noted that not every strain of HPV is carcinogenic 
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(1). There are over one hundred types of the HPV virus (16). Current 
epidemiological studies have determined that the following are low-risk 
types: 6, 11, 40, 42, 54, and 57 (16). These types limit their effects to 
genital warts that are benign lesions (16). 
 The most commonly implicated carcinogenic, high-risk, HPV 
types are the following: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 
and 58 (3, 16). These types induce dysplastic lesions, some of which 
are malignant cancers (16). HPV-16 is found in over fifty percent of 
cervical cancers (15). Integration of the viral genome into the host cell 
is required for transformation into cancerous cells (5). This may be 
due to the loss of E2 and E1 following integration, an ORF product 
responsible for repressing both E6 and E7 (1). In epithelial cells infected 
with low risk HPV, the virus remains in the episomal form with the 
E2 and E1 ORF products intact (15). Without these repressors, the 
uncontrolled expression of E6 and E7 leads to the degradation of p53 and 
retinoblastoma (16). 
 The early region is responsible for the pathogenicity of the virus. 
Amongst its six genes, two, E6 and E7, are very effective oncogenes. This 
paper will primarily focus on the role of E6 protein (pE6) in transforming 
the epithelial cells of the cervix into malignant carcinomas. 
 The E6 transcript was found in over ninety-two percent 
squamous cell carcinoma samples taken from Norwegian women (3). It 
is approximately 150 amino acids long with two zinc binding domains 
with the CXXC motif (18). The E6 ORF is expressed soon after infection 
with the HPV virus (4). The HPV virus uses this ORF product to disable 
the host cell’s sensory mechanisms for DNA damage (4). By disabling 
important checkpoints in the cell, disrupting communication, and other 
harmful events, this double stranded DNA virus is able to transform 
dormant epithelial cells into proliferating, immortal carcinomas (4). 
High Risk HPV pE6 targets p53 for destruction by 
ubiquitination:
 While pE6 has several mechanisms it uses to accomplish the 
overall goal of cellular transformation, its most famous pathway is the 
degradation of the genome protector, p53. This action was shown by 
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Demers et al (4). They demonstrated that transfection of HPV-16 pE6 
into primary human keratinocytes induced the elimination of p53 (4). 
The removal of p53 in the cell allows for the accumulation of mutations 
that contribute to the genomic instability of the cell and lead to 
transformation (11). 
 P53 is known to play an important role as a checkpoint in the 
cell cycle (4). It functions in the cell as a transcription factor for other 
genes that regulate the cell cycle (6). It acts as the signaling molecule 
to allow progression into both the synthesis phase and mitosis (4). This 
allows the cell to assess whether or not to replicate its DNA. If the DNA 
has, by some means, been damaged, p53 signals for cell cycle arrest and 
apoptosis.  It does this by up-regulating the expression of p21 (18).
 After treatment with low doses of actinomycin D, which induces 
DNA damage, epithelial cells that had been infected with this oncogene 
were unable to halt the cell cycle and continued into the synthesis phase 
(4).  This function plays a significant role in the carcinogenicity of this 
ORF product. HPV-16 pE6 binds with a host E3 ubiquitin ligase given 
the name of E6AP (5, 7). They, cooperatively, bind to p53 sand signal 
for degradation by the proteasome complex (5). To accomplish this task, 
HPV-16 pE6 requires the presence of six amino acids, out of the entire 
150 amino acid sequence, that contain a PDZ binding domain (5). 
 After transcription of the E6 gene, it undergoes splicing (11). One 
of the splicing patterns gives rise to E6*I, which can bind to full length 
pE6 (11). This binding controls the degradation of p53 during the course 
of the disease to prevent transformation into cancerous cells (11). Hence, 
mRNA processing can affect the carcinogenicity of HPV. In this way, HPV 
can regulate the expression of pE6 and determine when to transform the 
cells by mechanisms other than E2 expression (11). However, despite 
these posttranscriptional modifications, all of the infected cells were 
transformed into carcinomas over time (11). 
 Therefore, by eliminating the cell’s ability to assess DNA 
damage, epithelial cells continue through the cell cycle. This alone is 
able to transform normal epithelial cells into cancer. Unfortunately, 
the high risk types of HPV have other mechanisms they use to further 
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the transformation into cancerous cells (4). In combination with this 
carcinogenic blow, pE6 begins the process of transformation strong. 
High Risk HPV pE6/E6AP degrade PDZ domain containing 
proteins involved in tumor suppression:
 Proteins containing the PDZ domain have been implicated in 
tumor suppression (10). In epithelial cells, PDZ proteins are generally 
located at areas of cell-to-cell contact, such as tight junctions (18). Their 
role is thought to aide in signal transduction between cells (18).  
 DLG4 is a known target of HPV-18 pE6 and HPV-16 pE6 (10). 
Similar to the degradation of p53 by the proteasome complex, pE6 
targets DLG4, perhaps in conjunction with E6AP, for degradation by 
process of ubiquitination (10). In CaSki cells, DLG4 is known to have 
tumor suppression capabilities, and thus its degradation in HPV infected 
cells may be important in transformation (10). The complete mechanism 
by which DLG4 functions as a tumor suppressor is still unclear (10). Still, 
it is, obviously, important to note that pE6 can disable another tumor 
suppressor besides the p53. 
High Risk HPV pE6 binds to coactivators CBP /p300 to prevent 
p53 acetylation:
 Interferon is a signaling molecule the host cell produces in 
response to viral infection (6). Type I interferons not only signal for an 
immune response, but can also induce growth arrest (6). Interferon is 
linked with p53 in that p53 can influence the production of interferon by 
up-regulation and therefore, the host cell’s response to viral infection (6). 
 The activity of p53 is determined by coactivators CBP/p300 (6). 
They function as acetyltransferases for histones (6). Histone acetylation 
is very important for the expression of genes. By weakening the 
electrostatic interaction between DNA base pairs and the lysine residues 
on histone tails, the DNA encoding genes becomes accessible (7). These 
coactivators do not only acetylate histones, they also acetylate p53 itself 
(6). Acetylation of p53 increases its stability and transcriptional activity 
(6).  
 Not only does pE6 aide in the ubiquitination of p53, but it also 
diminishes p53’s transcriptional activity as well by binding to CBP/
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p300 (6). This sequestering activity prevents p53 acetylation (6). This 
decreased stability of the p53 weakens the remaining, non-ubiquitinated 
p53’s ability to halt the cell cycle. This is yet another mechanism by which 
high risk HPV virus eliminates cellular defense against uncontrolled 
proliferation. 
High Risk HPV E6 indirectly disrupts interferon response by 
infected cells:
 Among the various regulatory effects the p53 gene has, interferon 
response is one of them. When infection occurs, HPV E7 protein (pE7) 
stimulates the formation of interferon (6). This is, of course, detrimental 
to the virus. HPV, unfortunately, has a counteractive mechanism.  PE6 
eliminates the antiproliferative response the infected cell would have by 
eliminating the effects of the p53 through binding to CBP and p300 (6). 
 P53 regulates the type I interferon response (6). As mentioned 
before, type I interferons can induce an arrest in cell growth (6). Non-
acetylated p53 is unable to mediate the sensitivity of the infected cell to 
these interferons (6). PE6 induces this state of p53 by forming a trimeric 
complex with CBP, p300, and p53 (6). Therefore, infection by HPV 
bypasses antiviral systems that are functioning correctly. 
 Although the cells are properly responding to the HPV infection, 
they are no longer sensitive to the signal (6). This could create problems 
in treating HPV infections with interferons. If pE6 and pE7 are expressed 
without control, as they are after integration, then interferon treatment 
may not be effective. However, after early infection, interferon treatment 
could, potentially, be a reliable means of eliminating HPV infected cells. 
High Risk HPV pE6 induces polyploidy: 
 A common form, in solid tumors, of genomic instability is 
aneuploidy, which is thought to form from a tetraploid intermediate (8, 
14). Aneuploidy is a condition where the cell does not have a multiple 
of the haploid chromosome number. This condition is thought to be 
responsible for the different phenotypes of cancerous cells including 
the following: abnormal size, loss of contact with neighboring tissues, 
resistance to chemotherapy, increased proteins on the outer membrane, 
morphology, and others (14).  Aneuploidy forces the cell to enter into 
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a never ending cycle of redistributing genes to gain the most beneficial 
translational products, even at the expense of genomic stability (14). 
 Tetraploidy is thought to arise when, during mitosis, cells 
pause in the metaphase point for extended time periods (8). This is 
independent of a spindle checkpoint (8). The function of the postmitotic 
checkpoint is similar to the G1 and G2 checkpoints. In every instance, 
p21 is present and is mediated by p53 expression (8). Normally, these 
abnormal cells would not be able to continue through the cell cycle. 
However, given the absence of p53 and pRb in HPV-induced carcinomas, 
the cells progress to the synthesis phase of the cell cycle (8). 
 PE6 is known to cause polyploidy by preventing cell cycle 
arrest stimulated by microtubule disruption (8). This contributes to the 
genomic instability of HPV infected cells, which leads to the development 
of carcinomas (8). The abrogation of p53 would seem a likely pathway to 
mediate this activity, but studies in defective p53 cells demonstrated that 
pE6 still induced polyploidy (8). This is important because degradation 
of pE6 is never complete in cervical cancer cells (8). Therefore, pE6 must 
have some other means of inducing polyploidy in the presence of the p53. 
Hence, even without the degradation of p53, pE6 is able to induce 
genomic instability that leads to carcinomas in human epithelial cells. 
In conjunction with the p53 degradation in human epithelial cells, pE6 
further contributes to the transformation of these cells into cancer. 
High Risk HPV-16 E6, in conjunction with HPV-16 E7, 
demolishes the expression of TLR9:
 Toll-like receptors (TLRs) are responsible for recognizing 
molecular patterns associated with pathogens on both non-immune 
and immune cells (9). They are the receptors that bind to domains that 
originated from pathogens (9). TLR9 is responsible for recognizing 
foreign dsDNA-derived CpG motifs (9). Given the fact that HPV is a 
dsDNA virus, tests were done to ascertain whether TLR9 could bind to 
DNA motifs arising from HPV. The results established that TLR9 can 
recognize DNA motifs from HPV (9). 
 In HPV-16 infected cells, pE6 and pE7 were able to down-
regulate the TLR9 pathway (9). This is not done by process of 
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ubiquitination or protein alteration (9). Instead they eliminate yet 
another sensory mechanism by halting transcription of TLR9 by down-
regulating its promoter (9). Hence, pE6 not only bypasses the sensory 
mechanisms of the cell, but it evades the defense mechanism of the body 
by removing the receptor that could have detected its presence. This 
prevents any interference from the immune system that would quickly 
dispose of the virus before its most damaging work could be done (9). 
High Risk HPV-16 E6 activates hTERT:
 Telomerase, a four-subunit enzyme, is known to be involved 
in the immortalization of cancer cells (12, 18). It acts as the catalytic 
subunit of telomerase (12). By extending the telomeres, telomerase 
reverse transcriptase (hTERT) enables cells to bypass the Hayflick limit 
and prevent cell senescence (12 - 14). Cell senescence occurs when, 
after approximately fifty replications, the telomeres are shortened to 
the extent that chromosomes begin to fuse with each other and become 
aneuploid cells (13, 14). This triggers cell apoptosis if the damage cannot 
be fixed (13).  Telomerase uses RNA as a template, synthesizing hexamer 
repeat DNA to the 3’ end of telomeres (13, 18). This effectively lengthens 
the telomeres, prevents chromosomal fusion, and halts the signaling of 
apoptosis (13, 18). In most somatic cells, hTERT is down-regulated to 
prevent immortalization (13). In over ninety percent of cancerous cells, 
however, hTERT is active (13). Telomerase may also have proliferative 
activity independent of telomere extension as well (12). 
 HPV pE6 activates the TERT gene in cervical epithelial cells (12). 
In normal epithelial cells, histone deacetylases (HDAs) inactivate the 
hTERT promoter (12). By inhibiting HDA activity, the hTERT promoter 
can be activated (12). PE6 activates the hTERT promoter when H3 is 
acetylated; this is further enhanced by down-regulation of p300 and is 
dependent upon E6AP (12). This process begins early on during HPV 
infection, and continually increases until the increased transcription 
of hTERT is no longer dependent upon E6 (12). This trend follows the 
relative immortalization of the epithelial cells (12). 
 The activation by pE6 of hTERT is both p53-degradation and 
PDZ domain binding independent (12). This function is dependent 
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upon E6AP ligase (12). Although p300 knockdown is not the sole reason 
for hTERT up-regulation, it does seem to play an important role in 
telomerase activation (12). 
 In summary, pE6 has the capability of activating cellular 
machinery that immortalizes the cell. This transforms epithelial cells 
that previously had a timed death into cells that proliferate without 
consequences.  With the absence of p53 and pRb, DNA damage 
accumulates and telomerase prevents shortened chromosome ends 
from fusing with neighboring chromosomes. Therefore, it is yet another 
mechanism by which pE6 bypasses cellular checkpoints for DNA damage 
and, instead, transforms into carcinogenic cells.
Discussion:
  Given the examples of how a single protein infiltrates several 
elements of the cellular defense machinery, it is no wonder that a system 
of these proteins induces transformation of normal cervical epithelial 
cells into cancer. HPV is a virus that contains all of the necessary 
elements to hijack the cell into virus-making factories. HIV disrupts the 
immune system. HPV disrupts the cell. 
 Stripping the cells of their original function, HPV quickly 
disposes of the genome protectors. It disrupts both intracellular and 
intercellular communication. It activates genes for immortalization that, 
in a way, return the cells to an undifferentiated state. It induces genomic 
instability. All of these things are done within the first stages of infection. 
 Every year, approximately 6.5 million new HPV infections 
are reported in the United States alone (15). An estimated 20 million 
individuals are already infected with the virus (15). It is estimated that at 
least fifty percent of all sexually active individuals will acquire the virus 
by the age of 50 (15). To think that cervical cancer is caused by a virus of 
this competency is not a welcome thought. Causes for cancer have always 
been elusive or too ambiguous, but to find a culprit, and a culprit that is 
highly efficient at transforming these cells, has spurred research around 
the world. Recently, a vaccine has been introduced that may hold the 
key for prevention, but treatments for this deadly virus still fall in the 
category of barbaric killing of cells, without much differentiation between 
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the infected and the normal. 
 HPV remains a virus of interest, not only for clinical reasons, 
but for the understanding of the cell cycle in humans. HPV abolishes 
checkpoints in the cell cycle through various mechanisms. Further 
understanding of the viral mechanisms of transformation could enlighten 
researchers about the pathways cells take to become cancer without viral 
influence.  This information could be vital in developing new cancer 
treatments and more insight into cell senescence in general. 
 If scientists can understand the viral pathway high-risk HPV 
uses to transform cervical epithelial cells into carcinomas, then they can 
understand more about cellular immortalization. HPV-infected cells 
provide an excellent source for testing telomerase activity, not only for 
cancer treatment, but for potential uses in prolonging life.
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